Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 17/20 | 0.43 |
| ▸ | AURKA | O14965 | 15/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619167 | 0.81 | RPS6KB1 (0.38) | RPS6KB1AURKAAURKBPARP1PDPK1 | |
| SCHEMBL16619215 | 0.77 | PARP1 (0.46) | RPS6KB1AURKAAURKBPARP1 | |
| SCHEMBL4612903 | 0.77 | PARP1 (0.50) | RPS6KB1AURKAAURKBPARP1PDPK1 | |
| SCHEMBL29467366 | 0.77 | PARP1 (0.50) | RPS6KB1AURKAAURKBPARP1PDPK1 | |
| SCHEMBL29832249 | 0.77 | PARP1 (0.50) | RPS6KB1AURKAAURKBPARP1PDPK1 | |
| SCHEMBL18066324 | 0.74 | PARP1 (0.48) | RPS6KB1AURKAAURKBPARP1PDPK1 | |
| SCHEMBL30565302 | 0.74 | JAK2 (0.34) | RPS6KB1AURKAAURKBSMN1; SMN2 | |
| SCHEMBL6748668 | 0.73 | WDR5 (0.68) | WDR5KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL16619169 | 0.72 | MAPT (0.50) | RPS6KB1AURKAAURKBKDM4EPOLB | |
| SCHEMBL29013084 | 0.69 | WDR5 (0.49) | PARP1WDR5KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052500-B1 | INHIBITORS OF 5'-NUCLEOTIDASES AND THERAPEUTIC USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2018-01-03 | — | — | EP | claimed |
| US-9783541-B2 | 5′-nucleotidase inhibitors and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2017-10-10 | — | — | US | claimed |
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-09-22 | — | — | US | claimed |
| EP-3052500-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | Centre National De La Recherche Scientifique (FR) | 2016-08-10 | — | — | EP | claimed |
| WO-2015049447-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2015-04-09 | — | — | WO | claimed |
| EP-3052500-B1 | INHIBITORS OF 5'-NUCLEOTIDASES AND THERAPEUTIC USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2018-01-03 | — | — | EP | disclosed |
| US-9783541-B2 | 5′-nucleotidase inhibitors and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-09-22 | — | — | US | disclosed |
| EP-3052500-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | Centre National De La Recherche Scientifique (FR) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049447-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | NTPCR, NT5E, PNP | RPS6KB1 1967/4885AURKA 2015/4885AURKB 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.